Intellectual Ventures and the University of British Columbia to Collaborate

The Invention Development Fund of Intellectual Ventures (IV), The University of British Columbia (UBC) and BC Cancer Agency have entered into an agreement to further develop and commercialize a new pelvic fracture technology developed by clinicians and engineers at the BC Cancer Agency and Vancouver General Hospital. This minimally invasive technology can accelerate pelvic fracture treatment and recovery by replacing traditional screws used to fix pelvic ring fractures.

Under the agreement, the Invention Development Fund will provide funds to UBC that will support a clinical proof of concept of the technology. Following the proof of concept, the Invention Development Fund hopes to license the technology and associated intellectual property to a company that can bring the technology to market. By working with Intellectual Ventures, UBC and the BC Cancer Agency can more efficiently move their technology breakthrough beyond the research lab.

"This collaboration with Intellectual Ventures aims to enhance the commercialization pipelines available to UBC and its affiliated teaching hospitals and helps us achieve our goal of bringing world leading technologies to the marketplace for the betterment of society at large," said Angus Livingstone, Managing Director of UBC’s University-Industry Liaison Office. 

"Intellectual Ventures is proud of its ongoing collaboration with UBC, one of the world’s leading research universities," said Eric Bell, Senior Director, Future Surgery Team at Intellectual Ventures. "IV is committed to the entire invention life-cycle, including building, refining, and testing the best inventions and then bringing them to the functional prototype stage and beyond. This unique agreement with UBC helps us make our long-term vision a reality.”

Downloads